Unknown PHASE3 INTERVENTIONAL NCT00323219

Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department

Sponsor: University of British Columbia

Interventions Cefazolin and Moxifloxacin

Updated 5 times since 2017 Last updated: Feb 6, 2012 Started: Jan 31, 2004 Primary completion: Dec 31, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00323219, this PHASE3 trial focuses on Cellulitis and remains ongoing. Sponsored by University of British Columbia, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of British Columbia

Data source: University of British Columbia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada